Upadacitinib

Upadacitinib

Chemical structure of Upadacitinib

Upadacitinib is a medication used in the treatment of several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. It is classified as a Janus kinase inhibitor, specifically targeting the JAK1 enzyme.

Medical Uses

Upadacitinib is primarily prescribed for adults with moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It is also approved for the treatment of active psoriatic arthritis and moderate to severe atopic dermatitis.

Mechanism of Action

Upadacitinib works by inhibiting the activity of the Janus kinase 1 (JAK1) enzyme, which plays a crucial role in the signaling pathways of various inflammatory cytokines. By blocking JAK1, upadacitinib reduces the inflammatory response that contributes to the symptoms of autoimmune diseases.

Side Effects

Common side effects of upadacitinib include upper respiratory tract infections, nausea, cough, and fever. Serious side effects may include increased risk of infections, thrombosis, and gastrointestinal perforation. Patients are advised to undergo regular monitoring for these potential adverse effects.

Approval and Regulation

Upadacitinib was approved by the United States Food and Drug Administration (FDA) in 2019 for the treatment of rheumatoid arthritis. It has since received approval for additional indications, including psoriatic arthritis and atopic dermatitis, in various countries.

Related Pages

• Rheumatoid arthritis
• Psoriatic arthritis
• Atopic dermatitis
• Janus kinase inhibitor